1. Home
  2. XFOR vs NTIC Comparison

XFOR vs NTIC Comparison

Compare XFOR & NTIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XFOR
  • NTIC
  • Stock Information
  • Founded
  • XFOR 2014
  • NTIC 1970
  • Country
  • XFOR United States
  • NTIC United States
  • Employees
  • XFOR N/A
  • NTIC N/A
  • Industry
  • XFOR Biotechnology: Biological Products (No Diagnostic Substances)
  • NTIC Industrial Specialties
  • Sector
  • XFOR Health Care
  • NTIC Industrials
  • Exchange
  • XFOR Nasdaq
  • NTIC Nasdaq
  • Market Cap
  • XFOR 118.4M
  • NTIC 105.9M
  • IPO Year
  • XFOR N/A
  • NTIC N/A
  • Fundamental
  • Price
  • XFOR $3.37
  • NTIC $7.27
  • Analyst Decision
  • XFOR Strong Buy
  • NTIC Buy
  • Analyst Count
  • XFOR 3
  • NTIC 1
  • Target Price
  • XFOR $72.33
  • NTIC $20.00
  • AVG Volume (30 Days)
  • XFOR 146.4K
  • NTIC 38.8K
  • Earning Date
  • XFOR 05-01-2025
  • NTIC 04-10-2025
  • Dividend Yield
  • XFOR N/A
  • NTIC 3.03%
  • EPS Growth
  • XFOR N/A
  • NTIC N/A
  • EPS
  • XFOR 2.16
  • NTIC 0.38
  • Revenue
  • XFOR $31,364,000.00
  • NTIC $84,445,763.00
  • Revenue This Year
  • XFOR $355.69
  • NTIC $2.05
  • Revenue Next Year
  • XFOR $140.28
  • NTIC $4.70
  • P/E Ratio
  • XFOR $1.56
  • NTIC $19.05
  • Revenue Growth
  • XFOR N/A
  • NTIC 2.11
  • 52 Week Low
  • XFOR $3.05
  • NTIC $6.75
  • 52 Week High
  • XFOR $34.20
  • NTIC $19.63
  • Technical
  • Relative Strength Index (RSI)
  • XFOR 22.18
  • NTIC 31.35
  • Support Level
  • XFOR $3.05
  • NTIC $7.33
  • Resistance Level
  • XFOR $3.41
  • NTIC $7.49
  • Average True Range (ATR)
  • XFOR 0.62
  • NTIC 0.21
  • MACD
  • XFOR -0.02
  • NTIC 0.13
  • Stochastic Oscillator
  • XFOR 8.94
  • NTIC 42.62

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

About NTIC Northern Technologies International Corporation

Northern Technologies International Corp, or NTIC is a United States-based firm that develops and markets environmentally beneficial products and services world-wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company.

Share on Social Networks: